Integrilin eptifibatide: Marketed

CORR reported that in the first phase of a U.S. Phase II dose-ranging study of Integrilin in combination with Genentech Inc.'s TNKase tenecteplase fibrinolytic (an engineered version of tPA) in 190 patients with heart attacks, treatment with an Integrilin bolus of 180 ug/kg followed by 2 ug/kg/min infusion and a second 180 ug/kg bolus plus a half dose bolus of TNKase after 10 minutes resulted in restoration of normal blood flow (TIMI grade III) through blocked arteries in 70% of patients within 60 minutes of treatment. The treatment resulted in blood flow of TIMI grade II or III in blocked arteries in 96% of patients in the trial, which is called the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) study. ...